Functional leukocyte administration in protection against experimental neonatal infection.
Studies have shown that human neonates who develop group B streptococcal sepsis usually lack opsonic antibody (Ab) to their infecting strain and that these neonates may also have impaired polymorphonuclear leukocyte (PMN) function. The present study was designed to determine the efficacy of administration of PMNs or opsonic Ab-containing serum in protecting against group B streptococcal infection in a newborn rat model. After intraperitoneal (IP) injection of congruent to 5 X 10(6) streptococci, animals received separate IP injections of saline, serum lacking opsonic antibody (Ab negative), Ab positive serum or washed adult human PMNs (2 X 10(6)). The mortality rate in 55 neonatal rats infected with group B streptococci who received saline or Ab negative serum was 91%. In contrast, 40 animals who received adult human PMNs at the time of inoculation had a survival rate of 50% (P less than 0.001). Human serum containing opsonic antibody also provided significant protection against mortality in this model (survival rate 51%, P less than 0.001). Leukocytes from normal term neonates, stressed neonates, or ones pretreated with cytochalasin B offered les protection than did functional adult human cell (P less than 0.001).
D000328:Adult; D000818:Animals; D001803:Blood Transfusion; D003571:Cytochalasin B / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000276:immunology / Q000517:prevention & control*; D009504:Neutrophils / Q000637:transplantation*; D009895:Opsonin Proteins / Q000008:administration & dosage; D011292:Premedication; D051381:Rats; D013290:Streptococcal Infections / Q000276:immunology / Q000401:mortality / Q000517:prevention & control*; D013292:Streptococcus agalactiae
D009895:Opsonin Proteins; D003571:Cytochalasin B